vs
Side-by-side financial comparison of Brookfield Asset Management Ltd. (BAM) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
Brookfield Asset Management Ltd. is the larger business by last-quarter revenue ($1.3B vs $598.7M, roughly 2.2× EXELIXIS, INC.). Brookfield Asset Management Ltd. runs the higher net margin — 43.8% vs 40.8%, a 3.0% gap on every dollar of revenue. On growth, Brookfield Asset Management Ltd. posted the faster year-over-year revenue change (23.8% vs 5.6%). Over the past eight quarters, Brookfield Asset Management Ltd.'s revenue compounded faster (30.5% CAGR vs 18.7%).
Brookfield Asset Management Ltd. is a Canadian-American alternative asset manager. The company was founded in December 2022 as a spin-off of the asset management operations of Brookfield Corporation, and manages investments across real estate, infrastructure, renewable energy, private equity, and credit markets globally.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
BAM vs EXEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $598.7M |
| Net Profit | $586.0M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | — | 39.3% |
| Net Margin | 43.8% | 40.8% |
| Revenue YoY | 23.8% | 5.6% |
| Net Profit YoY | 15.6% | 74.8% |
| EPS (diluted) | $0.38 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $598.7M | ||
| Q4 25 | $1.1B | $597.8M | ||
| Q3 25 | $974.0M | $568.3M | ||
| Q2 25 | $931.0M | $555.4M | ||
| Q1 25 | $954.0M | $566.8M | ||
| Q3 24 | $873.0M | $539.5M | ||
| Q2 24 | $821.0M | $637.2M | ||
| Q1 24 | $786.0M | $425.2M |
| Q1 26 | $586.0M | $244.5M | ||
| Q4 25 | $615.0M | $193.6M | ||
| Q3 25 | $692.0M | $184.8M | ||
| Q2 25 | $584.0M | $159.6M | ||
| Q1 25 | $507.0M | $139.9M | ||
| Q3 24 | $537.0M | $118.0M | ||
| Q2 24 | $124.0M | $226.1M | ||
| Q1 24 | $373.0M | $37.3M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% | ||
| Q1 24 | — | 95.0% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | 84.2% | 39.6% | ||
| Q3 25 | 79.1% | 37.6% | ||
| Q2 25 | 70.8% | 33.6% | ||
| Q1 25 | 61.0% | 28.8% | ||
| Q3 24 | 72.5% | 25.2% | ||
| Q2 24 | 80.4% | 43.3% | ||
| Q1 24 | 56.5% | 6.9% |
| Q1 26 | 43.8% | 40.8% | ||
| Q4 25 | 56.7% | 32.4% | ||
| Q3 25 | 71.0% | 32.5% | ||
| Q2 25 | 62.7% | 28.7% | ||
| Q1 25 | 53.1% | 24.7% | ||
| Q3 24 | 61.5% | 21.9% | ||
| Q2 24 | 15.1% | 35.5% | ||
| Q1 24 | 47.5% | 8.8% |
| Q1 26 | $0.38 | $0.89 | ||
| Q4 25 | — | $0.69 | ||
| Q3 25 | — | $0.65 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | — | $0.77 | ||
| Q1 24 | — | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.6M | $2.2B |
| Total Assets | $17.9M | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.0M | $1.1B | ||
| Q4 25 | $1.6B | $988.5M | ||
| Q3 25 | $1.1B | $791.1M | ||
| Q2 25 | $480.0M | $1.0B | ||
| Q1 25 | $332.0M | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $10.0M | $1.0B | ||
| Q1 24 | — | $963.3M |
| Q1 26 | $8.6M | $2.2B | ||
| Q4 25 | $8.9B | $2.2B | ||
| Q3 25 | $8.5B | $2.0B | ||
| Q2 25 | $8.5B | $2.1B | ||
| Q1 25 | $8.5B | $2.2B | ||
| Q3 24 | $9.0B | $2.3B | ||
| Q2 24 | $3.2B | $2.1B | ||
| Q1 24 | $2.2B | $2.1B |
| Q1 26 | $17.9M | $2.8B | ||
| Q4 25 | $17.0B | $2.8B | ||
| Q3 25 | $16.5B | $2.7B | ||
| Q2 25 | $16.1B | $2.8B | ||
| Q1 25 | $15.0B | $2.9B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | $4.2B | $2.8B | ||
| Q1 24 | — | $2.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $333.5M |
| Free Cash FlowOCF − Capex | — | $332.4M |
| FCF MarginFCF / Revenue | — | 55.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $562.0M | $290.3M | ||
| Q3 25 | $745.0M | $49.0M | ||
| Q2 25 | $529.0M | $211.4M | ||
| Q1 25 | $265.0M | $240.3M | ||
| Q3 24 | $567.0M | $271.3M | ||
| Q2 24 | $159.0M | $119.5M | ||
| Q1 24 | $516.0M | $68.8M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M | ||
| Q1 24 | — | $59.1M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% | ||
| Q1 24 | — | 13.9% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 2.3% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | 0.91× | 1.50× | ||
| Q3 25 | 1.08× | 0.27× | ||
| Q2 25 | 0.91× | 1.32× | ||
| Q1 25 | 0.52× | 1.72× | ||
| Q3 24 | 1.06× | 2.30× | ||
| Q2 24 | 1.28× | 0.53× | ||
| Q1 24 | 1.38× | 1.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAM
| Management and incentive fee revenues | $990.0M | 74% |
| Other revenues | $236.0M | 18% |
| Other | $112.0M | 8% |
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
